Enanta Pharmaceuticals Inc Stock Price, News & Analysis

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that data from its hepatitis B virus (HBV) development program and non-alcoholic steatohepatitis (NASH) out-licensing program will be presented at the EASL International Liver Congress 2022 from June 22-26 in London. The presentations will include findings from Phase 1b studies of EDP-514, a core inhibitor for HBV, and results from EDP-297, a Farnesoid X receptor agonist for NASH, as well as data on HSD17B13 enzyme inhibition.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced CEO Jay R. Luly, Ph.D., will participate in two fireside chats in June 2022. The events include the Jefferies Healthcare Conference on June 9 at 9:00 a.m. ET and the JMP Securities Life Sciences Conference on June 16 at 9:30 a.m. ET. Webcast links will be available on Enanta's website, along with replays for 30 days post-event. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with candidates for RSV, COVID-19, and HBV under development.

Enanta Pharmaceuticals (NASDAQ: ENTA) announced topline results from its Phase 2b RSVP study of EDP-938 for RSV treatment, which did not meet its primary endpoint of clinical symptom reduction. However, a statistically significant number of subjects achieved undetectable RSV RNA by Day 5. The study demonstrated EDP-938's safety and tolerability. Enanta plans to continue development in high-risk populations, emphasizing the urgency for effective treatments in these groups. Future studies, including pediatric and high-risk adult populations, are underway.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported $18.7 million in royalty revenue for Q2 2022, a decrease from $20.1 million in Q2 2021. The net loss widened to $33.6 million, or $1.63 per share, compared to a loss of $22.0 million, or $1.09 per share, year-on-year. The company expects topline data from the Phase 2b RSVP study for EDP-938 and preliminary results from the Phase 1 EDP-235 study this quarter, with Fast Track designations granted for both. Enanta’s cash reserves stand at $322.5 million, expected to last for at least two years, supporting ongoing development programs.

Enanta Pharmaceuticals plans to report its financial results for the fiscal second quarter ended March 31, 2022, on May 9, 2022. A conference call will follow at 4:30 p.m. ET to discuss results and updates on the company's research pipeline, which focuses on small molecule drugs for viral infections and liver diseases, including targets like RSV, COVID-19, and HBV. Enanta's R&D is funded by royalties from HCV products developed in collaboration with AbbVie, notably Glecaprevir, part of its leading treatment for chronic HCV infections.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced that the FDA has granted Fast Track designation for EDP-235, an oral COVID-19 treatment targeting the coronavirus 3CL protease. This designation allows for expedited development due to the ongoing need for effective treatments against SARS-CoV-2. EDP-235 is currently undergoing a Phase 1 study assessing its safety and dosage. Preclinical data indicates it effectively blocks SARS-CoV-2 replication, positioning it as a leading candidate among direct-acting antivirals. Enanta expects to share Phase 1 data next quarter.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that its CEO, Jay R. Luly, Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 4:40 p.m. ET. Investors can access a live webcast on Enanta's website under the "Events and Presentations" section, with a replay available for 30 days post-event. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates targeting RSV, SARS-CoV-2, and HBV. The company is funded by royalties from its HCV collaboration with AbbVie.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced the publication of positive results from its Phase 2a human challenge study of EDP-938 for treating respiratory syncytial virus (RSV) in The New England Journal of Medicine. The study demonstrated significant reductions in viral load and symptom scores compared to placebo, with p-values <0.001. EDP-938 exhibited good pharmacokinetics and a favorable safety profile, being well tolerated without serious adverse events. The company is advancing EDP-938 through further clinical studies, including Phase 2 studies in pediatric patients and other groups.

Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-235, a novel coronavirus 3CL protease inhibitor aimed at treating COVID-19. This milestone is crucial as SARS-CoV-2 continues to pose a global health threat, with EDP-235 designed for once-daily oral administration. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers. Promising preclinical data indicate EDP-235's potent antiviral activity, with an exceptional EC90 of 33 nanomolar, positioning it as a potential best-in-class treatment. Initial results are expected in Q2 2022, with further developments planned for later in the year.